Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602198 · ClinicalTrials.gov registry record · NA
Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients
A NA study, sponsored by The Cleveland Clinic.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT01602198: Clinical Trial NA study, sponsored by The Cleveland Clinic.
NCT01602198 is a NA study that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01602198, a NA study, was terminated before completion, sponsored by The Cleveland Clinic.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The goal of this project is to determine if task-activated fMRI is sensitive to the central cholinergic deficit associated with Mild Cognitive Impairment.
Interventions
- DRUG Placebo transdermal patch
- DRUG Exelon [rivastigmine] transdermal patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-06 |
| Est. Completion | 2013-01 |
| Phase | NA |
Why NCT01602198 stopped before completion
NCT01602198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo transdermal patch is the first listed.
NCT01602198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01602198 about?
NCT01602198 is a clinical study titled "Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients". The goal of this project is to determine if task-activated fMRI is sensitive to the central cholinergic deficit associated with Mild Cognitive Impairment.
What is the current status of trial NCT01602198?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2011-06. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01602198?
The interventions under investigation include: Placebo transdermal patch (DRUG), Exelon [rivastigmine] transdermal patch (DRUG).
Who is sponsoring clinical trial NCT01602198?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01602198's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia